Says in “strong position” to advance innovative medicines. Says outlook of business remains “very strong.” Comments taken from Q4 earnings conference call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Morning Movers: Eli Lilly rises, Boston Scientific falls after quarterly results
- AbbVie reports Q4 adjusted EPS $2.71, consensus $2.65
- AbbVie sees FY26 adjusted EPS $14.37-$14.57, consensus $14.22
- Options Volatility and Implied Earnings Moves Today, February 04, 2026
- Is AbbVie Stock (ABBV) a Good Buy ahead of Q4 Earnings?